2m 2m 2m 2m 2m 2m 2m
DRUGS MADE (DMAA)
NASDAQ
$10.61+$0.005 (+0.05%)
Price as of Jun 03, 2026 3:59 PM EDT- N/AMarket Cap
- 4.48%1-Year Change
- Shell CompaniesIndustry
DRUGS MADE (DMAA)
$10.61+$0.005 (+0.05%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | N/A N/A | N/A N/A | |
Cost of Revenue | 141,976 N/A | N/A N/A | |
Gross Profit | -141,976 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | N/A N/A | N/A N/A | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | |
Total Operating Expenses | 2.8M +906.28% | 279,845 N/A | |
Operating Profit | -2.8M +906.28% | -279,845 N/A | |
Interest Income | 8.8M N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 8.8M N/A | 0 N/A | |
Total Nonoperating Income and Expense | 8.8M N/A | N/A N/A | |
Income before Taxes | -2.8M +906.28% | -279,845 N/A | |
Income Taxes | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | 5.9M +2,222.83% | -279,845 N/A | |
Net Income from Continuing Operations Applicable to Common | 5.9M +2,222.83% | -279,845 N/A | |
Basic EPS and Net Income | 0.19 +733.33% | -0.03 N/A | |
Diluted EPS and Net Income | 0.19 +733.33% | -0.03 N/A | |
Basic Weighted Average Shares | 21.0M +145.10% | 8.6M N/A | |
Diluted Weighted Average Shares | 21.0M +145.10% | 8.6M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 6,137 +354.26% | 1,351 N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 6,137 +354.26% | 1,351 N/A | |
Total Current Assets | 12,191 +144.26% | 4,991 N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | |
Total Long-Term Assets | 239.9M +43,852.39% | 545,833 N/A | |
Total Assets | 239.9M +43,456.35% | 550,824 N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 500,000 -24.51% | 662,324 N/A | |
Total Current Liabilities | 376,172 -52.72% | 795,669 N/A | |
Total Long-Term Debt | 1.1M -37.58% | 1.8M N/A | |
Total Long-Term Liabilities | 6.9M N/A | N/A N/A | |
Total Liabilities | 7.3M +814.47% | 795,669 N/A | |
Retained Earnings | -7.3M +2,496.10% | -279,845 N/A | |
Total Stockholders Equity | -7.3M +2,866.77% | -244,845 N/A | |
Total Shares Outstanding | 10.7M +8.72% | 9.9M N/A | |
Cash Flow | |||
Cash from Operating Activities | -539,187 +213.00% | -172,265 N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | -231.2M N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 231.7M +133,351.97% | 173,616 N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | 4.94% N/A | N/A N/A | |
Return on Equity | -158.23% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 0.03 N/A | N/A N/A | |
Cash Ratio | 0.02 N/A | N/A N/A | |
Debt-to-Equity Ratio | -0.22 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.007 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow